12:00 AM
Dec 21, 2009
 |  BC Week In Review  |  Company News  |  Deals

ChemGenex Pharmaceuticals, Hospira deal

ChemGenex granted Hospira exclusive rights to develop and commercialize omacetaxine mepesuccinate in Europe, the Middle East and parts of Africa. The natural alkaloid that targets the ribosome to inhibit synthesis of oncoproteins is...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >